Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant (NCT00639717), a na phase 2 study. The primary outcome is Percentage of Patients Alive at 6 Months.

2. Clinical Question

The clinical context in the registry is the prevention of serious and fatal acute GVHD after transplantation. Its description notes that reduced-intensity conditioning uses lower chemotherapy doses than full-intensity conditioning and may extend transplantation to patients for whom full-intensity treatment is not possible. It also describes a tension between GVHD and the graft-versus-leukemia effect: the study's stated aim is not necessarily to prevent every GVHD event, but to reduce serious and fatal acute disease.

The intervention combines two additions, etanercept and ECP, with tacrolimus and mycophenolate. Since both additions are made together and there is no concurrent control group, the design does not separate the contribution of either addition from the other or from the standard prophylaxis. The primary question is descriptive for the treated group rather than a direct test of comparative benefit.

3. Trial Design

This is a completed Phase 2 study sponsored by the University of Michigan Rogel Cancer Center. The registry lists enrollment of 48 and gives a study start of 2009-03 and primary completion of 2012-01. These registry entries describe the study record; they do not establish how many participants contributed data to every outcome analysis.

The design is recorded as single-group, with allocation not applicable and no masking. The intervention arm is titled “Etanercept and ECP.” It combines etanercept and extracorporeal photopheresis with standard GVHD prevention, listed as tacrolimus and mycophenolate, in patients undergoing reduced-intensity unrelated-donor hematopoietic stem cell transplantation. The description says etanercept is given twice weekly, starting on the day of conditioning and continuing until 8 weeks post-transplant. The ECP schedule is cut off in the registry record, so its full timing and schedule are not reported there.

A single-group study can describe outcomes observed among participants receiving the combined regimen. It cannot, by itself, distinguish the regimen's effect from the expected course of disease, differences among participants, or other aspects of transplantation care. Without a concurrent control arm, a contrast with standard prophylaxis alone is not part of the registered design. The record does not describe random assignment or masking; it identifies the study as unmasked.

The study lists five outcome measures overall, including the primary endpoint of the percentage of patients alive at 6 months. Secondary outcomes include the percentage experiencing GVHD, circulating plasma markers after transplant, and regulatory T cell numbers post-transplant. The registry reports zero analyses. The analysis methods, participant flow, and analysis populations are not reported in the registry record. Consequently, the design details support understanding what was investigated, but do not supply enough information to reconstruct how each outcome was analyzed.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Patients Alive at 6 Months, measured over 6 months.

The primary endpoint is the percentage of patients alive at 6 months, described as overall survival at 6 months. It is a binary outcome at a specified time: a participant is classified according to whether they are alive at that time. The registry identifies the unit as a percentage of patients and names a 95% confidence interval as the dispersion measure.

Overall survival is a broad endpoint because it captures survival regardless of the cause of death. In general, a fixed-time survival proportion can make an outcome readily interpretable to clinical readers. It does not, on its own, explain why deaths occurred, distinguish causes of death, or describe the timing of events throughout follow-up. Those questions require additional outcome definitions and analyses.

The registry record does not report the observed percentage alive at 6 months or its confidence interval. It also does not describe the primary-outcome analysis population, the handling of participants whose status at 6 months is unknown, or the approach to censoring. Therefore, the endpoint definition can be described, but the result and its precision cannot be assessed from the registry record. No conclusion about survival under the regimen can be drawn from an endpoint title alone.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record identifies a percentage as the primary outcome measure and a 95% confidence interval as its dispersion measure. The record does not provide the endpoint estimate or interval itself, nor does it specify the statistical procedure used to calculate it. The methods below explain general statistical ideas relevant to this type of outcome, not methods confirmed as used in the study.

What does a confidence interval communicate?

In general, a confidence interval expresses the uncertainty around an estimate, with a wider interval indicating less precision and a narrower interval indicating greater precision under the method's assumptions. A 95% confidence interval is not a guarantee that the true value lies inside a particular calculated interval. Its interpretation depends on the statistical procedure and the conditions that procedure assumes. Here, the registry names a 95% confidence interval but does not report its endpoints, so neither the estimate nor its precision can be judged.

What does a percentage measure?

In general, a percentage for a binary outcome describes the share of the analysis population meeting a defined condition. For survival at a fixed time, the condition is being alive at that time. Interpretation depends on who is included in the denominator and how incomplete follow-up is handled. The registry does not report the analysis population or explain missing-status handling for the primary endpoint. The enrollment entry should not be assumed to be the endpoint denominator.

Why does the single-group design matter?

In general, an outcome rate in a single group is an estimate of what occurred in that group under the observed care and follow-up. It does not supply a randomized counterfactual for what would have occurred to comparable participants without the added interventions. Differences between a single-group estimate and an external rate can reflect differences in populations, supportive care, outcome definitions, or follow-up, as well as treatment. The registry classifies this study as single-group and lists no concurrent comparator.

Because etanercept and ECP are used together with standard prophylaxis, the design also does not identify their separate contributions. This is a feature of the intervention contrast, not a statistical adjustment that can be resolved from an outcome percentage alone.

How should the planning illustrations be understood?

General sample-size planning uses assumptions about the effect to be detected, the significance level, allocation, and statistical approximation. The registry's planning description says the illustrations use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the target effect expressed as a stated fraction of the observed effect. It says that time-to-event illustrations count total events, while other illustrations count participants per arm. These are planning illustrations, not the study's design justification or evidence of observed power. The record does not report the trial's own sample-size justification, and no planning illustration should be read as a result observed in this single-group trial.

For general interpretation, power is a property of a specified design and assumed effect, not a post-study measure proving that a finding is reliable. A planning calculation cannot compensate for an absent outcome estimate, an absent confidence interval, or the lack of a concurrent comparison. The registry does not report an inferential test for the primary outcome, and no p-value is reported.

Why can adverse-event counts be hard to compare?

In general, adverse-event summaries can count participants with an event, event episodes, or event terms, and these are not interchangeable. A participant may experience more than one type of event, and a term may be recorded according to rules not visible in a brief registry summary. The record gives affected and at-risk counts for serious and other adverse events and lists selected serious-event terms by percentage. It does not explain the coding rules, event attribution, overlap, or collection period. These figures therefore describe the registry entries but do not provide a controlled comparison of safety.

Over-dispersion is a general issue when event counts vary more than a simple statistical model expects; it can make uncertainty estimates too optimistic if a model fails to allow for that variability. The registry does not report an event-count model, repeated-event analysis, or any other safety analysis. This concept should not be taken as evidence that over-dispersion occurred in this study.

In sum, the record contains the endpoint definition, some adverse-event summaries, and a description of planning assumptions, but not the primary estimate, its interval, or a detailed analysis plan. General statistical explanations clarify what such outputs would mean; they do not fill the gaps in the reported study results.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Etanercept and ECP")
n      <- c(48)
events <- c(40)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Etanercept and ECP  48  40  83.3  69.8  92.5  70.4  91.3  70.3  91.2

11. Multiplicity, Missing Data and Analysis Populations

The registry lists five outcome measures, with the primary outcome defined as the percentage of patients alive at 6 months. It also names secondary outcomes concerning GVHD, circulating plasma markers, and regulatory T cell numbers. The record reports zero analyses. It does not describe a statistical analysis plan, prespecified testing hierarchy, multiplicity adjustment, or which secondary outcomes were intended to support confirmatory rather than exploratory conclusions. These details are not reported in the registry record.

In general, testing many outcomes can increase the chance of observing an apparently notable result by chance if the analyses are interpreted without accounting for multiplicity. A prespecified hierarchy or adjustment can address some of that issue, but neither should be assumed without a reported plan. Since numerical results and tests for the listed outcomes are not present, the degree of multiplicity concern cannot be evaluated from this entry.

The primary endpoint's analysis population is not reported. The record also does not describe missing data, loss to follow-up, whether all enrolled participants were analyzed, or how unknown survival status at 6 months was handled. Enrollment of 48 is not enough to establish the denominator for the primary result. Likewise, the adverse-event at-risk counts do not define the analysis population for survival or for the secondary outcomes.

These omissions matter because estimates can depend on which participants contribute data and how incomplete observations are treated. In general, missingness can affect both the estimate and its uncertainty; a complete-case analysis and an approach that accounts for censoring may answer different questions. No such approach is specified in the registry record. The record also does not report interim analyses, stopping rules, or a sample-size justification. No assumptions about those procedures can be made from the study's completed status.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: blood bone marrow - other (6.2%), cardiac ischemia/infarction (4.2%), diarrhea (2.1%), gastrointestinal - other (2.1%), ileus, gi obstruction (2.1%).

The registry lists 19 participants affected by serious adverse events among 48 at risk in the Etanercept and ECP group. For other adverse events, it lists 47 affected among 48 at risk. These are descriptive summaries within the listed study group. They do not compare the intervention with standard prophylaxis alone, because a concurrent comparator group is not reported.

The registry lists selected serious adverse-event terms and percentages: Blood Bone Marrow - Other, 6.2%; Cardiac ischemia/infarction, 4.2%; Diarrhea, 2.1%; Gastrointestinal - Other, 2.1%; Ileus, GI Obstruction, 2.1%; and Vomiting, 2.1%. The entry does not explain whether these percentages refer to participants or events, whether individuals may appear under more than one term, or whether the listed terms are exhaustive. They should be read as the registry's reported term-level figures rather than added together or treated as mutually exclusive categories.

The death count is not reported in the registry record. The record also does not give event timing, duration, severity grading details, attribution to treatment, or the methods for collecting events. Without those details and a comparison group, the adverse-event summaries cannot establish whether the combined regimen changed risk relative to another approach.

13. What the Result Does, and Does Not, Mean

The registry record describes a completed Phase 2, single-group study of etanercept and ECP added to tacrolimus and mycophenolate for GVHD prophylaxis in reduced-intensity unrelated-donor transplantation. Its primary endpoint is overall survival at 6 months. This defines the question the study set out to address, but it is not itself a result.

The numerical primary outcome and its 95% confidence interval are not reported in the registry record. The record therefore does not establish the observed six-month survival percentage or how precisely it was estimated. The listed enrollment cannot stand in for the missing result, and completion status does not show what the outcome was.

Even if the primary estimate were available, the single-group design would describe outcomes in the treated group rather than provide a randomized treatment contrast. It would not show what would have happened to similar participants receiving standard prophylaxis without the additions. Nor could the combined regimen distinguish the separate contribution of etanercept from that of ECP. These limits apply to interpretation of effectiveness and safety.

The adverse-event figures provide descriptive counts and selected term-level percentages for the listed group. They do not establish a relative safety difference. The record lacks a concurrent comparator and does not report details needed to interpret overlap, attribution, timing, or collection. The secondary outcomes are named, but their results are not reported in the registry record.

In general, a clinical trial result is most informative when the outcome definition, analysis population, estimate, uncertainty, and comparison design can be considered together. For this record, the intervention and endpoint are identifiable, but key pieces needed for outcome interpretation are absent. Accordingly, the registry entry supports a description of the study's design and listed adverse-event summaries, not a conclusion that the regimen does or does not change survival, GVHD, or other clinical outcomes.

14. Why This Trial Matters Statistically

This study is statistically noteworthy because it combines two additional prophylactic approaches in a population defined by reduced-intensity unrelated-donor transplantation, while using a single-group design. That design can document outcomes among participants receiving the combined regimen, but it cannot produce a randomized estimate of the effect of adding the regimen compared with standard prophylaxis alone.

The registry's focus on overall survival at 6 months also illustrates the difference between an outcome definition and a reported result. A survival percentage and its confidence interval would allow readers to assess the observed value and its precision. The registry names those measures but does not report the result. Consequently, statistical interpretation must stop short of evaluating the survival estimate.

The intervention includes both etanercept and ECP alongside tacrolimus and mycophenolate. Without separate intervention groups, the design cannot isolate the effects of the two additions. This is relevant when interpreting any future or external evidence about the components: a combined-treatment result should not automatically be attributed to either one alone.

The entry also makes visible the limits of abbreviated safety reporting. Affected and at-risk counts and selected term percentages are useful descriptive details, but they do not establish comparative safety. Interpretation depends on definitions, event attribution, overlap, follow-up, and a comparator; those details are not reported in the registry record.

Finally, the record distinguishes neither its own design rationale nor its analysis procedures in detail. Planning illustrations are explicitly described as illustrations based on an observed effect, not as the trial's design justification or observed power. This distinction matters: a planning calculation is not a substitute for transparent reporting of the actual endpoint estimate, uncertainty, and analysis population.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The central limitation for interpreting outcomes is that the registry names the primary endpoint but does not report its estimate or confidence interval. The entry therefore does not allow readers to assess the observed six-month survival proportion or its precision. Results for the listed secondary outcomes are also not reported in the registry record.

The single-group design has no concurrent comparator, so outcome patterns cannot be attributed to adding etanercept and ECP rather than other features of care or the participants' underlying clinical course. Because both additions are combined, the design also cannot distinguish their individual contributions. The record lists no allocation or masking beyond classifying allocation as not applicable and masking as none.

Important analysis details are missing. The primary analysis population, denominator, handling of unknown survival status, and treatment of missing data are not reported in the registry record. The statistical analysis methods, multiplicity strategy, interim analyses, and sample-size justification are likewise not reported. Enrollment should not be assumed to equal the number analyzed for each outcome.

The ECP schedule is incomplete in the arm description. Safety reporting is limited to listed counts and selected serious-event terms; the record does not describe event definitions, attribution, overlap, timing, or collection methods. A death count is not reported in the registry record. These limitations restrict both outcome interpretation and comparison with other studies.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant — NCT00639717.
• Registry record last updated 2017-08-01; status last verified 2017-07.
• Results first posted 2014-09-25.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes NCT00639717, a completed Phase 2, single-group study sponsored by the University of Michigan Rogel Cancer Center. It lists enrollment of 48, a start date of 2009-03, and primary completion in 2012-01. The study concerns reduced-intensity unrelated-donor hematopoietic stem cell transplantation and GVHD prophylaxis.

The intervention combines etanercept and ECP with standard prophylaxis using tacrolimus and mycophenolate. The primary outcome is the percentage of patients alive at 6 months, with a 95% confidence interval named as the dispersion measure. The numerical primary result and interval are not reported in the registry record. The study is unmasked and has no listed concurrent comparator.

The record lists secondary outcomes involving GVHD, circulating plasma markers, and regulatory T cell numbers. It also reports serious and other adverse-event counts and selected serious-event percentages. Analysis populations, detailed statistical methods, and the primary endpoint result are not reported.